Welcome to Awesome Blog Design perfect blog

Tag: #Therapy

Business, Healthcare

DESTINY-Breast05 head-to-head phase 3 trial of ENHERTU® versus T-DM1 initiated in patients with HER2 positive early breast cancer at high risk after neo-adjuvant therapy

TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced the initiation of DESTINY-Breast05, a global phase 3, head-to-head trial of ENHERTU® (fam-trastuzumab deruxtecan-nxki) versus ado-trastuzumab emtansine (T-DM1) as adjuvant therapy in patients with

Healthcare

Merck’s KEYTRUDA® (pembrolizumab) receives two new approvals in Japan

KEYTRUDA Now Approved for Patients With PD-L1-Positive Esophageal Squamous Cell Carcinoma Who Have Progressed After Chemotherapy and for a Six-Week Dosing Schedule Across All Adult Indications Six-Week Dosing Schedule for KEYTRUDA Now Approved in Japan, US and Europe KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck

Business, Healthcare

Merck’s KEYTRUDA® (pembrolizumab) in combination with chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in locally advanced or first-line metastatic esophageal cancer

KEYTRUDA Is First Anti-PD-1 Therapy in Combination With Chemotherapy to Show Superior Survival Benefit as First-Line Treatment for Patients With Esophageal Cancer Regardless of Histology Results of Phase 3 KEYNOTE-590 Trial to be Submitted to Global Regulatory Authorities KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck